Cardiology Plus,
Journal Year:
2025,
Volume and Issue:
unknown
Published: March 18, 2025
Anti-obesity
medications
have
gone
through
a
tumultuous
course
of
approvals
and
withdrawals,
often
triggered
by
serious
cardiovascular
complications.
Early
agents,
including
amphetamines
fenfluramine–phentermine,
were
once
widely
used
but
ultimately
banned
or
voluntarily
withdrawn
due
to
Sibutramine
followed
similar
trajectory
when
clinical
trials
revealed
increased
event
rates,
prompting
its
market
withdrawal.
Lorcaserin,
initially
promising
for
weight
management
without
significant
risks,
was
after
postmarketing
surveillance
potential
link
cancer
incidence.
Although
more
recent
medications,
orlistat,
phentermine–topiramate,
naltrexone–bupropion,
remain
available,
their
cardiometabolic
benefits
are
modest,
long-term
outcome
data
inconclusive
still
lacking.
The
emergence
glucagon-like
peptide
1
(GLP-1)
receptor
agonists
co-agonists
has
transformed
obesity
management.
Liraglutide,
semaglutide,
tirzepatide,
originally
developed
type
2
diabetes,
demonstrated
substantial
sustained
loss
along
with
notable
improvements
in
markers.
In
high-risk
populations,
randomized
liraglutide
semaglutide
also
shown
reductions
major
adverse
events.
Moreover,
tirzepatide
exhibited
patients
heart
failure
preserved
ejection
fraction
obesity.
Overall,
GLP-1
hold
promise,
however,
questions
regarding
safety
effects
broader
populations.
history
approval
withdrawal
anti-obesity
underscores
the
importance
surveillance.
As
evidence
continues
accumulate,
balance
between
efficacy
will
guide
optimal
use
both
risk
reduction.
Obesity Pillars,
Journal Year:
2025,
Volume and Issue:
14, P. 100170 - 100170
Published: Feb. 26, 2025
Obesity
is
considered
a
chronic
disease
and
influenced
by
biological,
environmental,
behavioral
factors
that
can
contribute
to
its
progression.
Although
lifestyle
changes
are
integral
treating
obesity
maintaining
healthful
weight,
weight
reduction
from
intervention
alone
often
insufficient
because
neurophysiologic
may
work
against
such
in
behavior.
Research
suggests
the
mechanisms
underlying
food
cravings
overlap
with
dopaminergic
signaling
brain
pathways
involved
addiction.
As
result,
patients
who
differentially
impacted
have
better
outcomes
treatments
targeting
neural
systems
implicated
both
homeostatic
hedonic
consumption
or
addictive
behaviors.
In
this
clinical
review,
we
describe
safety
efficacy
data
for
fixed-dose,
extended-release
combination
of
naltrexone
bupropion
(NB-ER)
compared
monotherapy
constituents
(naltrexone
bupropion),
as
well
discuss
appropriate
use
NB-ER
treat
obesity.
approved
treatment
obesity,
studies
showing
achieve
significant
placebo
when
combined
reduced-calorie
diet
increased
physical
activity.
Across
phase
3
trials,
responders
had
mean
body
11.7
%
at
56
weeks.
Of
note,
unique
naltrexone,
an
opioid
receptor
antagonist,
bupropion,
norepinephrine-dopamine
reuptake
inhibitor
associated
stimulating
pro-opiomelanocortin
cells
(POMC),
together
target
POMC
prevent
endogenous
negative
feedback,
thereby
decreasing
appetite
improving
weight-related
outcomes.
Unlike
component
drugs,
optimized
The
should
consider
specific
characteristics
adiposity-related
complications
individual.
Nutrients,
Journal Year:
2025,
Volume and Issue:
17(6), P. 1023 - 1023
Published: March 14, 2025
Background/Objectives:
Fasting
and
physical
exertion
positively
affect
body
mass
composition.
This
study
aimed
to
examine
the
effects
of
changes
induced
by
eight
days
water-only
fasting
a
test
their
influence
on
satisfaction
image
parameters
in
middle-aged
men.
Methods:
Fifteen
participants
were
assessed
for
(height,
mass,
composition)
psychological
(body
satisfaction,
evaluation
parts,
determinants)
aspects
before
after
intervention,
both
at
rest
post-exercise.
Correlation
concordance
coefficients
calculated
analyzed
variables.
Results:
It
was
found
that
intervention
led
reduction
favorable
shift
composition,
while
also
increasing
with
one’s
its
specific
parts.
impacted
volunteers’
self-assessment
health
status.
Selected
remained
an
average
level
male
population
did
not
change
following
fasting.
Attitudes
toward
weight
control
methods
perceived
effectiveness
either.
Participants
favored
reducing
food
intake
eliminating
high-calorie
products
from
diet,
rejecting
use
pathological
typically
associated
eating
disorders.
A
few
associations
between
corporeality
observed,
whereas
significant
correlations
parts
positive
confirmed.
Conclusions:
The
above
suggest
conditions
resulting
lead
components
but
do
alter
image.
Cardiology Plus,
Journal Year:
2025,
Volume and Issue:
unknown
Published: March 18, 2025
Anti-obesity
medications
have
gone
through
a
tumultuous
course
of
approvals
and
withdrawals,
often
triggered
by
serious
cardiovascular
complications.
Early
agents,
including
amphetamines
fenfluramine–phentermine,
were
once
widely
used
but
ultimately
banned
or
voluntarily
withdrawn
due
to
Sibutramine
followed
similar
trajectory
when
clinical
trials
revealed
increased
event
rates,
prompting
its
market
withdrawal.
Lorcaserin,
initially
promising
for
weight
management
without
significant
risks,
was
after
postmarketing
surveillance
potential
link
cancer
incidence.
Although
more
recent
medications,
orlistat,
phentermine–topiramate,
naltrexone–bupropion,
remain
available,
their
cardiometabolic
benefits
are
modest,
long-term
outcome
data
inconclusive
still
lacking.
The
emergence
glucagon-like
peptide
1
(GLP-1)
receptor
agonists
co-agonists
has
transformed
obesity
management.
Liraglutide,
semaglutide,
tirzepatide,
originally
developed
type
2
diabetes,
demonstrated
substantial
sustained
loss
along
with
notable
improvements
in
markers.
In
high-risk
populations,
randomized
liraglutide
semaglutide
also
shown
reductions
major
adverse
events.
Moreover,
tirzepatide
exhibited
patients
heart
failure
preserved
ejection
fraction
obesity.
Overall,
GLP-1
hold
promise,
however,
questions
regarding
safety
effects
broader
populations.
history
approval
withdrawal
anti-obesity
underscores
the
importance
surveillance.
As
evidence
continues
accumulate,
balance
between
efficacy
will
guide
optimal
use
both
risk
reduction.
